Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy

Epilepsy Research

Volumn 85, Issue 1, 2009, Pages 89-95

  Iannetti, Paola ^a   Parisi, Pasquale ^a   Spalice, Alberto ^a   Ruggieri, Martino ^b   Zara, Federico ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Calcium channel blocker; Channelopathy; Severe myoclonic epilepsy in infancy; SMEI; Verapamil

Indexed keywords

ACETAZOLAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; GLYCOPROTEIN P; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL; VOLTAGE GATED SODIUM CHANNEL;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADOLESCENT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CHILD; CHROMOSOME 2Q; CLINICAL PROTOCOL; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG USE; EPILEPTIC STATE; EXON; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENETIC ANALYSIS; GRAND MAL SEIZURE; HUMAN; INFANT; LANGUAGE DEVELOPMENT; MISSENSE MUTATION; MOTOR DEVELOPMENT; MULTIDRUG RESISTANCE; MYOCLONUS EPILEPSY; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADOLESCENT; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 2; ELECTROENCEPHALOGRAPHY; EPILEPSIES, MYOCLONIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; SODIUM CHANNELS; VERAPAMIL;

EID: 67349253535     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.02.014     Document Type: Article

References (25)

1. Abrahim A., Luurtsema G., Bauer M., Karch R., Lubberink M., Pataraia E., Joukhadar C., Kletter K., Lammertsma A.A., Baumgartner C., Müller M., and Langer O. Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 116-123
2. Bahls F.H., Ozuna J., and Ritchie D.E. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 41 (1991) 740-742
3. Catteral W.A., Perez-Reyes E., Snutch T.P., and Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57 (2005) 411-425
4. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., and De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 68 (2001) 1327-1332
5. Depienne C., Trouillard O., Saint-Martin C., An I., Bouteiller D., Carpentier W., Keren B., Abert B., Gautier A., Baulac S., Arzimanoglou A., Cazeneuve C., Nabbout R., and Leguern E. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J. Med. Genet. 46 (2009) 183-191
6. Dravet C., Bureau M., Oguni H., Fukuyama Y., and Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv. Neurol. 95 (2005) 71-102
7. Fujiwara T. Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies. Epilepsy Res. 70 Suppl. 1 (2006) S223-S230
8. George Jr. A.L. Inherited channelopathies associated with epilepsy. Epilepsy Curr. 4 (2004) 65-70
9. Harkin L.A., Bowser D.N., Dibbens L.M., Singh R., Phillips F., Wallace R.H., Richards M.C., Williams D.A., Mulley J.C., Berkovic S.F., Scheffer I.E., and Petrou S. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am. J. Hum. Genet. 70 (2002) 530-536
10. Iannetti P., Spalice A., and Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 (2005) 967-969
11. Landry Y., and Gies J.P. Drugs and their molecular targets: an updated overview. Fundam. Clin. Pharmacol. 1 (2008) 1-18
12. Loscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia 48 Suppl. 8 (2007) 74-77
13. Luurtsema G., Molthoff C.F., Schuit R.C., et al. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol. 32 (2005) 87-93
14. Malacarne M., Madia F., Gennaro E., Vacca D., Güney A.I., Buono S., Bernardina B.D., Gaggero R., Gobbi G., Lispi M.L., Malamaci D., Melideo G., Roccella M., Sferro C., Tiberti A., Vanadia F., Vigevano F., Viri F., Vitali M.R., Bricarelli F.D., Bianchi A., and Zara F. Lack of SCN1A mutations in familial febrileseizures. Epilepsia 43 (2002) 559-562
15. Meisler M.H., and Kearney J.A. Sodium channel mutations in epilepsy and other neurological disorders. J. Clin. Invest. 115 (2005) 2010-2017
16. Ohmori I., Ouchida M., Ohtsuka Y., Oka E., and Shimizu K. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem. Biophys. Res. Commun. 295 (2002) 17-23
17. Ohmori I., Kahlig K.M., Rhodes T.H., Wang D.W., and George Jr. A.L. Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy. Epilepsia 47 (2006) 1636-1642
18. Ohmori I., Ouchida M., Miki T., Mimaki N., Kiyonaka S., Nishiki T., Tomizawa K., Mori Y., and Matsui H. A CACNB4 mutation shows that altered Ca(v)2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. Neurobiol. Dis. 32 (2008) 349-354
19. Schmidt D., and Loescher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
20. 2+ channels as therapeutic targets in the nervous system. Curr. Opin. Pharmacol. 8 (2008) 33-41
21. Spampanato J., Escayg A., Meisler M.H., and Goldin A.L. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J. Neurosci. 21 (2001) 7481-7490
22. Syvanen S., Hooker A., Rahman O., Wilking H., Blomquist G., Langstrom B., Bergstrom M., and Hammarlund-Udenaes M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci. 97 (2008) 5386-5400
23. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Marchi N., Vezzani A., and Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47 (2006) 672-680
24. Wang J.W., Kurahashi H., Ishii A., Kojima T., Ohfu M., Inoue T., Ogawa A., Yasumoto S., Oguni H., Kure S., Fujii T., Ito M., Okuno T., Shirasaka Y., Natsume J., Hasegawa A., Konagaya A., Kaneko S., and Hirose S. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 49 (2008) 1528-1534
25. Wurpel J.N., and Iyer S.N. Calcium channel blockers verapamil and nipodipine inhibit kindling in adult and immature rats. Epilepsia 35 (1994) 443-449